Efficacy and safety of once-weekly semaglutide 20 Mg versus 10 Mg in patients with type 2 diabetes (sustain forte): A double-blind, randomised, phase 3B trial
The reason that we dont, as patients have ownership of our data, is because theres an arbitrage system where this data is bought and sold by various entities outside the patient, and theres a huge market and profitability incentive to keep this data away from patients ownership into the hands of these other entities, whether its the insurer, the PBM, the hospital system, the physician, the pharmacist, whatever it is
Clinical studies highlight greater weight loss success and additional cardiovascular benefits with GLP-1s
Quitting smoking is beneficial not just for reducing clot risk but also for overall health
Oral semaglutide 50 mg also reduced high-sensitivity C-reactive protein by 57.3%, a marker of systemic inflammation used to evaluate future cardiovascular risk